Kaleido Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 06, 2020 08:30 ET
|
Kaleido Biosciences
LEXINGTON, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
Kaleido Biosciences to Advance KB174 for Hepatic Encephalopathy Based on Positive Top-Line Results from a Clinical Study in Patients with Cirrhosis
December 12, 2019 08:00 ET
|
Kaleido Biosciences
- KB174 Exceeded the Targeted Reduction in a Biomarker of Microbiome Ammonia Production- KB174 Was Well Tolerated and No Clinically Significant or Serious Treatment-Related Adverse Events Were...
Kaleido Biosciences Appoints William Duke as Chief Financial Officer
November 06, 2019 08:00 ET
|
Kaleido Biosciences
LEXINGTON, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
Kaleido Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
October 30, 2019 16:05 ET
|
Kaleido Biosciences
- Executing Pipeline Towards Key Clinical Data Readouts in Q4 2019 and 2020 - Focusing Resources on Pipeline Programs and Extending Cash Runway LEXINGTON, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE)...
Kaleido Biosciences and Washington University School of Medicine to Collaborate on Exploring the Influence of Microbiome Metabolic Therapies (MMT™) on Physiology and Metabolism
October 22, 2019 08:00 ET
|
Kaleido Biosciences
LEXINGTON, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
Kaleido Biosciences Presents Ex Vivo Data of KB109 Demonstrating Reduction of Multi-drug Resistant Pathogens at IDWeek 2019™
October 03, 2019 08:00 ET
|
Kaleido Biosciences
Additional Presentation on Platform at Upcoming Keystone Symposia on the Microbiome: Therapeutic Implications LEXINGTON, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq:...
Kaleido Biosciences Announces Appointment of Jean Mixer to its Board of Directors
September 30, 2019 08:00 ET
|
Kaleido Biosciences
LEXINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
Kaleido Biosciences Announces CFO Transition
September 26, 2019 16:10 ET
|
Kaleido Biosciences
LEXINGTON, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
Kaleido Biosciences to Collaborate with Gustave Roussy Cancer Center to Develop Microbiome Metabolic Therapies (MMT™) in Immuno-oncology
September 09, 2019 07:30 ET
|
Kaleido Biosciences
LEXINGTON, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
Kaleido Biosciences Presents Data from Clinical Study of KB195 in Patients with Urea Cycle Disorders at Society for the Study of Inborn Errors of Metabolism Annual Symposium
September 03, 2019 08:00 ET
|
Kaleido Biosciences
Data Demonstrate Safety and Tolerability of Microbiome Metabolic Therapy (MMT™) Candidate KB195 and Potential for Effect on Nitrogen Metabolism, a Biomarker of Ammonia Production LEXINGTON, Mass.,...